Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions

Peter Flatt, B. D. Green

Research output: Contribution to journalArticlepeer-review


increasing prevalence of obesity combined with longevity will produce an epidemic of Type 2 (non-insulin-dependent) diabetes in the next 20 years. This. disease is associated with defects in insulin secretion, specifically abnormalities of insulin secretory kinetics and pancreatic beta-cell glucose responsiveness. Mechanisms underlying beta-cell dysfunction include glucose toxicity, lipotoxicity and beta-cell hyperactivity. Defects at various sites in beta-cell signal transduction pathways contribute, but no single lesion can account for the common form of Type 2 diabetes. Recent studies highlight diverse beta-cell actions of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These intestinal hormones target the beta-cell to stimulate glucose-dependent insulin secretion through activation of protein kinase A and associated pathways. Both increase gene expression and proinsulin biosynthesis, protect against apoptosis and stimulate replication/neogenesis of beta-cells. Incretin hormones therefore represent an exciting future multi-action solution to correct beta-cell defect in Type 2 diabetes.
Original languageEnglish
Pages (from-to)774-778
JournalBiochemical Society Transactions
Issue numberPart 5
Publication statusPublished (in print/issue) - Nov 2006


Dive into the research topics of 'Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions'. Together they form a unique fingerprint.

Cite this